I'm all in favor of mergers and acquisitions -- the more we get, the higher the stock market goes -- but I am not in favor of making conclusions based on tips about deals.
Reports of two potentially major buyouts show the risks of late-cycle corporate bond investing.
Let others wait and see if someone comes in with a better offer than Alphabet's bid for Fitbit; this value investor is taking his profit and leaving the table.
The buyout offer for Tiffany & Co. from Louis Vuitton's parent could spark more deals; this trio of sagging stocks could make for targets.
The maker of wearable fitness devices has seen its stock sprint higher on the buyout news after languishing this summer near multi-year lows.
These stocks are priced for total imperfection. That's just what you want.
Biogen, Novartis and Bristol-Myers Squibb are among the drugmakers that gave investors reasons for cheer on Tuesday.
Let's review the charts and indicators to see what they are showing today.
M&A activity has generally slowed.
Black-market vaping has made the entire cannabis group toxic.